product name Carteolol HCl
Description: Carteolol HCl is a β-adrenoceptor antagonist, used for the treatment of glaucoma. Carteolol has been found to be a nonconventional partial agonist, which causes agonistic effects via interaction with the low-affinity propranolol-resistant site of β1-adrenoceptors and antagonistic actions by the high-affinity site of the same receptors.
References: J Pharmacol Exp Ther. 2005 Dec;315(3):1386-95; Int Ophthalmol. 1989 Jan;13(1-2):85-9.
328.83
Formula
C16H25ClN2O3
CAS No.
51781-21-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 65 mg/mL (197.7 mM)
Water: <1 mg/mL
Ethanol: 65 mg/mL (197.7 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19397793
| In Vitro |
In vitro activity: Previous findings demonstrate that carteolol, unlike xamoterol, is a nonconventional partial agonist, which causes agonistic effects via interaction with the low-affinity propranolol-resistant site of β1-adrenoceptors and antagonistic actions by the high-affinity site of the same receptors. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Both 8-OH carteolol and carteolol suppressed the water-load induced intraocular pressure (IOP) rise in rabbits. 8-OH carteolol was more effective in suppressing water-load induced IOP rise in rabbits compared with carteolol on equimolar basis. Both 8-OH carteololand carteolol caused a significant decrease in IOP in monkeys. 8-OH carteolol was estimated to be more potent than carteolol in lowering IOP on equimolar basis in monkeys. |
| Animal model | |
| Formulation & Dosage | |
| References | J Pharmacol Exp Ther. 2005 Dec;315(3):1386-95; Int Ophthalmol. 1989 Jan;13(1-2):85-9. |
Related Posts
product name Carteolol HCl
Description: Carteolol HCl is a β-adrenoceptor antagonist, used for the treatment of glaucoma. Carteolol has been found to be a nonconventional partial agonist, which causes agonistic effects via interaction with the low-affinity propranolol-resistant site of β1-adrenoceptors and antagonistic actions by the high-affinity site of the same receptors.
References: J Pharmacol Exp Ther. 2005 Dec;315(3):1386-95; Int Ophthalmol. 1989 Jan;13(1-2):85-9.
328.83
Formula
C16H25ClN2O3
CAS No.
51781-21-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 65 mg/mL (197.7 mM)
Water: <1 mg/mL
Ethanol: 65 mg/mL (197.7 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19397793
| In Vitro |
In vitro activity: Previous findings demonstrate that carteolol, unlike xamoterol, is a nonconventional partial agonist, which causes agonistic effects via interaction with the low-affinity propranolol-resistant site of β1-adrenoceptors and antagonistic actions by the high-affinity site of the same receptors. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Both 8-OH carteolol and carteolol suppressed the water-load induced intraocular pressure (IOP) rise in rabbits. 8-OH carteolol was more effective in suppressing water-load induced IOP rise in rabbits compared with carteolol on equimolar basis. Both 8-OH carteololand carteolol caused a significant decrease in IOP in monkeys. 8-OH carteolol was estimated to be more potent than carteolol in lowering IOP on equimolar basis in monkeys. |
| Animal model | |
| Formulation & Dosage | |
| References | J Pharmacol Exp Ther. 2005 Dec;315(3):1386-95; Int Ophthalmol. 1989 Jan;13(1-2):85-9. |